Choroidal Neovascularization Market: By Product Type, By Treatment, By Diagnosis, By Application, By End Users and Region Forecast 2020-2031
Choroidal Neovascularization Market size was valued at US$ 7.1 million in 2024 and is expected to reach US$ 12.2 million by 2031, growing at a significant CAGR of 8.0% from 2025-2031. Choroidal Neovascularization (CNV) is the formation of new blood vessels in the choroid layer of the eye, which is associated with excessive amounts of vascular endothelial growth factor, and is the common cause of neovascular degenerative maculopathy, and can be exacerbated by extreme myopia, malignant myopic degeneration, or age-related developments. Based on the application type, the malignant myopic degeneration segment is anticipated to dominate the market share over the forecast period.
According to a research report, the estimated number of people with age-related macular degeneration will double by 2050, from 2.07 million to 5.44 million. Increased drug development and growing the market demand for hospitals and clinics will act as the growth drivers for the market, whereas complications associated with treatment and unavailability of appropriate treatment might pose as challenges for the market. Higher cases of age-related macular degeneration and increasing use of generic drugs are opportunities for market expansion.
Study Period
2025-2031Base Year
2024CAGR
8.0%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
The increasing prevalence of choroidal neovascularization cases, the increasing aging population, and rising government initiatives for the development of healthcare infrastructure are the major factors for the growth of the market. For instance, in Oct 2021, the FDA gave approval for Bausch Health Companies and Clearside Biomediclas’s Xiperetm for suprachoroidal use in the treatment of macular edema associated with uveitis. Additionally, increasing incidences of lifestyle-associated diseases such as high blood pressure, and diabetes is also supporting the growth of the market. Thus, the increased awareness, research and development for lysosomal storage disorders will lead to the growth of the market within the forecast period.
The market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The major risk factor for age-related macular degeneration is age, which rises from 2% for individuals aged 50-59, to about 30% for those aged 75 and older. The prevalence of visual impairment due to pathogenic myopia is reported to range from 0.1% to 0.5% in Europeans and 0.2%. to 1.4% in Americans and Asians. The North America market is expected to dominate the market over the forecast period, due to the increasing investments by healthcare providers for the treatment and rising research activities in the segment. Asia Pacific market is also growing at a faster rate owing to the presence of key generic pharmaceutical companies, and the increasing aged population in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 7.1 million |
|
Market Size in 2031 |
US$ 12.2 million |
|
Market CAGR |
8.0% |
|
By Product Type |
|
|
By Treatment Type |
|
|
By Diagnosis |
|
|
By Application |
|
|
By End User |
|
|
By Region |
|
Download Free Sample Report
Choroidal neovascularization market size was valued at US$ 7.1 million in 2024 and is expected to reach US$ 12.2 million by 2031, growing at a CAGR of 8.0%.
Higher cases of age-related macular degeneration and increasing use of generic drugs are the key opportunities for the market.
Increased drug development and growing demand for hospitals and clinics are the growth drivers in the market.
Bausch Health Companies Inc., Bayer AG, Gilead Sciences, Inc., Roche AG, MaaT Pharma, Novartis AG, Pfizer Inc., Quark Pharmaceuticals Inc., and Regeneron Pharmaceuticals Inc. are a few companies operating in the market.
| 1.Executive Summary |
| 2.Global Choroidal Neovascularization Market Introduction |
| 2.1.Global Choroidal Neovascularization Market - Taxonomy |
| 2.2.Global Choroidal Neovascularization Market - Definitions |
| 2.2.1.Product Type |
| 2.2.2.Treatment Type |
| 2.2.3.Diagnosis |
| 2.2.4.Application |
| 2.2.5.Region |
| 3.Global Choroidal Neovascularization Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Choroidal Neovascularization Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Choroidal Neovascularization Market By Product Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Intravenous |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Intravitreal |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6.Global Choroidal Neovascularization Market By Treatment Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Angiogenesis Inhibitors Injection |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Photodynamic Therapy |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Laser Photocoagulation |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Low-dose Radiation Therapy |
| 6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Surgery |
| 6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Choroidal Neovascularization Market By Diagnosis, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. Fluorescein Angiography |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Indocyanine Green Angiography |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Spectral Domain Optical Coherence Tomography |
| 7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Others |
| 7.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8.Global Choroidal Neovascularization Market By Application, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. Extreme Myopia |
| 8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Malignant Myopic Degeneration |
| 8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Age-Related Developments |
| 8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9.Global Choroidal Neovascularization Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Choroidal Neovascularization Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 10.1. Product Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Intravenous |
| 10.1.2.Intravitreal |
| 10.2. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Angiogenesis Inhibitors Injection |
| 10.2.2.Photodynamic Therapy |
| 10.2.3.Laser Photocoagulation |
| 10.2.4.Low-dose Radiation Therapy |
| 10.2.5.Surgery |
| 10.3. Diagnosis Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Fluorescein Angiography |
| 10.3.2.Indocyanine Green Angiography |
| 10.3.3.Spectral Domain Optical Coherence Tomography |
| 10.3.4.Others |
| 10.4. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Extreme Myopia |
| 10.4.2.Malignant Myopic Degeneration |
| 10.4.3.Age-Related Developments |
| 10.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Choroidal Neovascularization Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Intravenous |
| 11.1.2.Intravitreal |
| 11.2. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Angiogenesis Inhibitors Injection |
| 11.2.2.Photodynamic Therapy |
| 11.2.3.Laser Photocoagulation |
| 11.2.4.Low-dose Radiation Therapy |
| 11.2.5.Surgery |
| 11.3. Diagnosis Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Fluorescein Angiography |
| 11.3.2.Indocyanine Green Angiography |
| 11.3.3.Spectral Domain Optical Coherence Tomography |
| 11.3.4.Others |
| 11.4. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Extreme Myopia |
| 11.4.2.Malignant Myopic Degeneration |
| 11.4.3.Age-Related Developments |
| 11.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 12.Asia Pacific (APAC) Choroidal Neovascularization Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Intravenous |
| 12.1.2.Intravitreal |
| 12.2. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Angiogenesis Inhibitors Injection |
| 12.2.2.Photodynamic Therapy |
| 12.2.3.Laser Photocoagulation |
| 12.2.4.Low-dose Radiation Therapy |
| 12.2.5.Surgery |
| 12.3. Diagnosis Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Fluorescein Angiography |
| 12.3.2.Indocyanine Green Angiography |
| 12.3.3.Spectral Domain Optical Coherence Tomography |
| 12.3.4.Others |
| 12.4. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Extreme Myopia |
| 12.4.2.Malignant Myopic Degeneration |
| 12.4.3.Age-Related Developments |
| 12.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Choroidal Neovascularization Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Intravenous |
| 13.1.2.Intravitreal |
| 13.2. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Angiogenesis Inhibitors Injection |
| 13.2.2.Photodynamic Therapy |
| 13.2.3.Laser Photocoagulation |
| 13.2.4.Low-dose Radiation Therapy |
| 13.2.5.Surgery |
| 13.3. Diagnosis Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Fluorescein Angiography |
| 13.3.2.Indocyanine Green Angiography |
| 13.3.3.Spectral Domain Optical Coherence Tomography |
| 13.3.4.Others |
| 13.4. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Extreme Myopia |
| 13.4.2.Malignant Myopic Degeneration |
| 13.4.3.Age-Related Developments |
| 13.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Choroidal Neovascularization Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 14.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Intravenous |
| 14.1.2.Intravitreal |
| 14.2. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Angiogenesis Inhibitors Injection |
| 14.2.2.Photodynamic Therapy |
| 14.2.3.Laser Photocoagulation |
| 14.2.4.Low-dose Radiation Therapy |
| 14.2.5.Surgery |
| 14.3. Diagnosis Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Fluorescein Angiography |
| 14.3.2.Indocyanine Green Angiography |
| 14.3.3.Spectral Domain Optical Coherence Tomography |
| 14.3.4.Others |
| 14.4. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Extreme Myopia |
| 14.4.2.Malignant Myopic Degeneration |
| 14.4.3.Age-Related Developments |
| 14.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Bausch Health Companies Inc. |
| 15.2.2.Bayer AG |
| 15.2.3.Intas Pharmaceuticals |
| 15.2.4.Gilead Sciences, Inc. |
| 15.2.5.Roche AG |
| 15.2.6.MaaT Pharma |
| 15.2.7.Novartis AG |
| 15.2.8.Pfizer Inc. |
| 15.2.9.Quark Pharmaceuticals Inc. |
| 15.2.10.Regeneron Pharmaceuticals Inc. |
| 15.2.11.Sanwa Kagaku Kenkyusho Co. Ltd. |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
